Lip Clinical Trials

437 recruitingLast updated: July 25, 2026

There are 437 actively recruiting lip clinical trials across 71 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Beijing, Beijing Municipality, China, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Lip Trials at a Glance

437 actively recruiting trials for lip are listed on ClinicalTrialsFinder across 6 cities in 71 countries. The largest study group is Not Applicable with 148 trials, with the heaviest enrollment activity in Houston, Beijing, and Boston. Lead sponsors running lip studies include National Cancer Institute (NCI), Beijing Tiantan Hospital, and China Immunotech (Beijing) Biotechnology Co., Ltd..

Treatments under study

About Lip Clinical Trials

Looking for clinical trials for Lip? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lip trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lip clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 437 trials

Recruiting
Phase 3

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled192 locationsNCT06589804
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled582 locationsNCT03866382
Recruiting
Phase 1

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled19 locationsNCT07491172
Recruiting
Phase 3

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

Venous malformationsLymphatic MalformationsCLOVES Syndrome+1 more
Kaken Pharmaceutical150 enrolled1 locationNCT07285005
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled77 locationsNCT06371417
Recruiting
Phase 1

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+24 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Phase 3

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

Cardiovascular DiseasesAtherosclerosisLipoprotein(a)
Eli Lilly and Company252 enrolled58 locationsNCT07613294
Recruiting
Phase 2Phase 3

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

Mucopolysaccharidosis IIIMPS IIIASanfilippo Syndrome+1 more
Ultragenyx Pharmaceutical Inc36 enrolled5 locationsNCT02716246
Recruiting
Phase 1Phase 2

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

SarcomaSolid TumorLeiomyosarcoma+1 more
STORM Therapeutics LTD107 enrolled9 locationsNCT06975293
Recruiting
Not Applicable

Screening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders

Celiac Disease in ChildrenCongenital Heart DiseaseInflammatory Bowel Disease (IBD)+4 more
Alexandra Miriam Kiess600 enrolled1 locationNCT07716488
Recruiting

MEASuRE: Metreleptin Effectiveness And Safety Registry

Partial LipodystrophyGeneralised Lipodystrophy
Chiesi Farmaceutici S.p.A.100 enrolled28 locationsNCT02325674
Recruiting
Not Applicable

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

Obesity, OverweightDiabetesPrediabetes+3 more
Cambridge Health Alliance20 enrolled1 locationNCT06988462
Recruiting
Phase 1

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

HypercholesterolemiaHypertriglyceridemiaRefractory Hyperlipidemia
Verve Therapeutics, Inc.36 enrolled16 locationsNCT06451770
Recruiting
Phase 3

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Familial Partial Lipodystrophy
Chiesi Farmaceutici S.p.A.24 enrolled7 locationsNCT06679270
Recruiting
Not Applicable

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8+30 more
Emory University118 enrolled1 locationNCT06662058
Recruiting
Phase 1

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple Sites+7 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT03093909
Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled257 locationsNCT06422806
Recruiting

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Retroperitoneal Liposarcoma
Australia and New Zealand Sarcoma Association100 enrolled13 locationsNCT07377747
Recruiting

Assessment of Venous Insufficiency and Clinical Features in Lipedema

Disability PhysicalVenous InsufficiencyLipedema+1 more
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey82 enrolled1 locationNCT07603076